CD8A and hepatocellular carcinoma: Furthermore, in a mouse HCC model, anti-IL-10R administration delays tumor growth by reinvigorating CD8+ T cell infiltration and function to a similar extent as anti-PD-L1 administration (Xiao et al., 2016).